BPTH - Bio-Path Holdings, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.224
+0.004 (+1.772%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.220
Open0.220
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.215 - 0.230
52 Week Range0.180 - 1.380
Volume823,122
Avg. Volume618,234
Market Cap25.399M
Beta2.12
PE Ratio (TTM)N/A
EPS (TTM)-0.075
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • ACCESSWIRElast month

    Corporate News Blog - Valeant Pharma Completes Sale of its Obagi Medical Products Business

    Research Desk Line-up: Bio-Path Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Valeant ...

  • Bio-Path Holdings Inc (BPTH): How Does It Impact Your Portfolio?
    Simply Wall St.last month

    Bio-Path Holdings Inc (BPTH): How Does It Impact Your Portfolio?

    If you are looking to invest in Bio-Path Holdings Inc’s (NASDAQ:BPTH), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • Associated Presslast month

    Bio-Path reports 3Q loss

    The Bellaire, Texas-based company said it had a loss of 2 cents per share. In the final minutes of trading on Thursday, the company's shares hit 30 cents. A year ago, they were trading at $1.21. _____ ...

  • GlobeNewswirelast month

    Bio-Path Holdings Reports Third Quarter 2017 Financial Results

    HOUSTON, Nov. 09, 2017-- Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer ...

  • GlobeNewswirelast month

    Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts

    HOUSTON, Nov. 06, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid ...

  • GlobeNewswirelast month

    Bio-Path Holdings, Inc. Announces $4 Million Registered Direct Offering

    HOUSTON, Nov. 03, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid ...

  • ACCESSWIRE2 months ago

    Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)

    DALLAS, TX / ACCESSWIRE / October 23, 2017 / Bio-Path Holdings, Inc. (NASDAQ: BPTH): COMPANY DESCRIPTION Bio-Path Holdings, Inc. (Bio-Path) is a clinical stage biotechnology company that focuses on developing ...

  • Is It Time To Buy Bio-Path Holdings Inc (BPTH)?
    Simply Wall St.2 months ago

    Is It Time To Buy Bio-Path Holdings Inc (BPTH)?

    Bio-Path Holdings Inc (NASDAQ:BPTH), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM in the over the last fewRead More...

  • Associated Press4 months ago

    Bio-Path reports 2Q loss

    The Bellaire, Texas-based company said it had a loss of 3 cents per share. The company's shares closed at 35 cents. A year ago, they were trading at $1.73. _____ This story was generated by Automated Insights ...

  • Associated Press7 months ago

    Bio-Path reports 1Q loss

    The Bellaire, Texas-based company said it had a loss of 1 cent per share. The company's shares closed at 59 cents. A year ago, they were trading at $2.75. _____ This story was generated by Automated Insights ...

  • Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher
    Zacks8 months ago

    Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher

    Bio-Path Holdings, Inc. (BPTH) shares rose over 13% in the last trading session.

  • Associated Press9 months ago

    Bio-Path reports 4Q loss

    The Bellaire, Texas-based company said it had a loss of 1 cent per share. The biotechnology company posted revenue of $13,000 in the period. For the year, the company reported that its loss widened to ...